The Middle Eastern stock markets have recently experienced fluctuations, with Dubai's index snapping a five-day winning streak and Saudi Arabia's benchmark settling lower amid concerns about real estate supply and oil price volatility. Despite these challenges, the search for promising investment opportunities continues, particularly in the realm of penny stocks. While the term 'penny stock' might seem outdated, it remains relevant as these smaller or newer companies can offer significant growth potential when backed by strong financials and fundamentals.
Top 10 Penny Stocks In The Middle East
| Name | Share Price | Market Cap | Rewards & Risks |
| Katmerciler Arac Üstü Ekipman Sanayi ve Ticaret (IBSE:KATMR) | TRY1.70 | TRY1.83B | ✅ 2 ⚠️ 2 View Analysis > |
| Thob Al Aseel (SASE:4012) | SAR4.00 | SAR1.6B | ✅ 2 ⚠️ 1 View Analysis > |
| Alarum Technologies (TASE:ALAR) | ₪2.70 | ₪189.09M | ✅ 4 ⚠️ 2 View Analysis > |
| Terminal X Online (TASE:TRX) | ₪4.339 | ₪551.08M | ✅ 2 ⚠️ 0 View Analysis > |
| Oil Refineries (TASE:ORL) | ₪0.905 | ₪2.81B | ✅ 1 ⚠️ 2 View Analysis > |
| Tgi Infrastructures (TASE:TGI) | ₪2.311 | ₪171.8M | ✅ 2 ⚠️ 2 View Analysis > |
| Sharjah Cement and Industrial Development (PJSC) (ADX:SCIDC) | AED0.723 | AED439.77M | ✅ 2 ⚠️ 2 View Analysis > |
| Dubai National Insurance & Reinsurance (P.S.C.) (DFM:DNIR) | AED3.00 | AED361.51M | ✅ 2 ⚠️ 4 View Analysis > |
| E7 Group PJSC (ADX:E7) | AED1.03 | AED2.08B | ✅ 3 ⚠️ 2 View Analysis > |
| Dubai Investments PJSC (DFM:DIC) | AED2.40 | AED10.12B | ✅ 2 ⚠️ 3 View Analysis > |
Click here to see the full list of 93 stocks from our Middle Eastern Penny Stocks screener.
We'll examine a selection from our screener results.
Ajman Bank PJSC (DFM:AJMANBANK)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Ajman Bank PJSC offers a range of banking products and services to individuals, businesses, and government institutions in the United Arab Emirates, with a market cap of AED4.03 billion.
Operations: The company's revenue is derived from Treasury (AED113.94 million), Consumer Banking (AED266.56 million), and Wholesale Banking (AED454.45 million) segments within the United Arab Emirates.
Market Cap: AED4.03B
Ajman Bank PJSC, with a market cap of AED 4.03 billion, has shown financial resilience by becoming profitable in the past year despite a 1.6% annual earnings decline over five years. The bank maintains appropriate loan and deposit levels, with its Loans to Assets ratio at 57% and Loans to Deposits ratio at 67%. However, it faces challenges with high bad loans at 10.8%. Recently, Ajman Bank completed a $500 million fixed-income offering and reported improved Q1 net income of AED 134.68 million compared to AED 107.42 million last year. Its Price-To-Earnings ratio is favorable compared to the AE market average.
- Click to explore a detailed breakdown of our findings in Ajman Bank PJSC's financial health report.
- Understand Ajman Bank PJSC's track record by examining our performance history report.
Akfen Gayrimenkul Yatirim Ortakligi (IBSE:AKFGY)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Akfen Gayrimenkul Yatirim Ortakligi A.S. operates as a real estate investment trust, having transformed from Aksel Turizm Yatirimlari ve Isletmecilik AS, with a market capitalization of TRY8.19 billion.
Operations: Akfen Gayrimenkul Yatirim Ortakligi A.S. does not report specific revenue segments.
Market Cap: TRY8.19B
Akfen Gayrimenkul Yatirim Ortakligi A.S., with a market cap of TRY8.19 billion, has demonstrated robust financial performance despite some challenges. The company's earnings grew significantly by 54% over the past year, exceeding both its five-year average growth and the industry benchmark. However, it faces a substantial one-off gain of TRY1.4 billion affecting recent results, which may skew perceptions of its profitability. While short-term assets cover short-term liabilities comfortably, long-term liabilities remain uncovered by these assets. Despite this, the company maintains a low net debt to equity ratio and offers an attractive Price-To-Earnings ratio compared to the TR market average.
- Get an in-depth perspective on Akfen Gayrimenkul Yatirim Ortakligi's performance by reading our balance sheet health report here.
- Explore historical data to track Akfen Gayrimenkul Yatirim Ortakligi's performance over time in our past results report.
PlantArc Bio (TASE:PLNT)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: PlantArc Bio Ltd. is an Ag-Bio company focused on crop protection and yield enhancement, with a market cap of ₪7.65 million.
Operations: The company generates revenue from its Agricultural Biotech segment, totaling ₪4.40 million.
Market Cap: ₪7.65M
PlantArc Bio Ltd., with a market cap of ₪7.65 million, operates in the Ag-Bio sector focusing on crop protection and yield enhancement but remains pre-revenue with sales of only ₪4.4 million for 2024. Despite its unprofitability and negative return on equity, the company has managed to reduce losses over five years by 0.9% annually and maintains a cash runway exceeding three years without any debt burden. Shareholders have not faced significant dilution recently, although its share price has been highly volatile. The management team is experienced, averaging 4.7 years in tenure, providing some stability amid financial challenges.
- Unlock comprehensive insights into our analysis of PlantArc Bio stock in this financial health report.
- Gain insights into PlantArc Bio's historical outcomes by reviewing our past performance report.
Seize The Opportunity
- Unlock more gems! Our Middle Eastern Penny Stocks screener has unearthed 90 more companies for you to explore.Click here to unveil our expertly curated list of 93 Middle Eastern Penny Stocks.
- Curious About Other Options? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if PlantArc Bio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com